J Cancer 2020; 11(3):619-629. doi:10.7150/jca.33805 This issue Cite

Research Paper

Clinical prognostic implications of EPB41L4A expression in multiple myeloma

Weilong Zhang1*, Rui Lai2,4*, Xue He3*, Xiaoni Liu4, Ye Zhang5, Zuozhen Yang1, Ping Yang1, Jing Wang1, Kai Hu1, Xiaoliang Yuan4, Xiuru Zhang3✉, Weiyou Liu4✉, Hongmei Jing1✉

1. Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing, 100191, China
2. Department of the Respiratory medicine, The People's Hospital of Ruijin City, Ruijin, 342500, China
3. Department of Pathology, Beijing Tiantan Hospital, Capital Medical University, Beijing, 100070, China
4. Department of Respiratory Medicine, First Affiliated Hospital Gannan Medical University, Ganzhou, 341000, China
5. Melbourne School of Population and Global Health, The University of Melbourne, Victoria, 3010, Australia
*These authors contributed equally to this work.

Citation:
Zhang W, Lai R, He X, Liu X, Zhang Y, Yang Z, Yang P, Wang J, Hu K, Yuan X, Zhang X, Liu W, Jing H. Clinical prognostic implications of EPB41L4A expression in multiple myeloma. J Cancer 2020; 11(3):619-629. doi:10.7150/jca.33805. https://www.jcancer.org/v11p0619.htm
Other styles

File import instruction

Abstract

Background: Multiple myeloma (MM) is one of the most common incurable malignancies in malignant plasma cell disease. EPB41L4A is a target gene for the Wnt/β-catenin pathway, which is closely related to the survival of multiple myeloma cells. However, there is currently no research report on the prognostic significance of the EPB41L4A gene in MM.

Methods: We studied the biological significance and prognostic significance of EPB41L4A expression in MM by integrating 1956 MM samples from 7 datasets, and explored the relationship between EPB41L4A expression and MM ISS stage, molecular type, therapeutic response and survival.

Results: We found that the expression level of EPB41L4A is inversely proportional to the copy number of 1q21 (P = 3.4e-13). EPB41L4A was low expressed in MAF, MMSET and proliferating molecular typing patients (P <= 0.001). High expression of EPB41L4A can predict good survival in MM (EFS: P < 0.0001; OS: P < 0.0001). We found that patients with relapsed MM had lower expression levels of EPB41L4A than those without recurrence (P = 0.0039). We also found that EPB41L4A can predict the prognosis of MM patients may be related to DNA replication. These results indicate that the initial expression level of EPB41L4A can predict the prognosis of MM patients.

Conclusions: We found that the high expression of EPB41L4A predicts good survival level in MM.

Keywords: EPB41L4A, multiple myeloma, prognostic, gene expression profile.


Citation styles

APA
Zhang, W., Lai, R., He, X., Liu, X., Zhang, Y., Yang, Z., Yang, P., Wang, J., Hu, K., Yuan, X., Zhang, X., Liu, W., Jing, H. (2020). Clinical prognostic implications of EPB41L4A expression in multiple myeloma. Journal of Cancer, 11(3), 619-629. https://doi.org/10.7150/jca.33805.

ACS
Zhang, W.; Lai, R.; He, X.; Liu, X.; Zhang, Y.; Yang, Z.; Yang, P.; Wang, J.; Hu, K.; Yuan, X.; Zhang, X.; Liu, W.; Jing, H. Clinical prognostic implications of EPB41L4A expression in multiple myeloma. J. Cancer 2020, 11 (3), 619-629. DOI: 10.7150/jca.33805.

NLM
Zhang W, Lai R, He X, Liu X, Zhang Y, Yang Z, Yang P, Wang J, Hu K, Yuan X, Zhang X, Liu W, Jing H. Clinical prognostic implications of EPB41L4A expression in multiple myeloma. J Cancer 2020; 11(3):619-629. doi:10.7150/jca.33805. https://www.jcancer.org/v11p0619.htm

CSE
Zhang W, Lai R, He X, Liu X, Zhang Y, Yang Z, Yang P, Wang J, Hu K, Yuan X, Zhang X, Liu W, Jing H. 2020. Clinical prognostic implications of EPB41L4A expression in multiple myeloma. J Cancer. 11(3):619-629.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image